沙库巴曲缬沙坦用于急性前壁ST段抬高型心肌梗死行急诊PCI术后患者的临床疗效OACSTPCD

Objective To explore the clinical efficacy of sacubitril-valsartan on patients with acute anterior wall ST segment elevation myocardial infarction(STEMI)who undergoing emergency PCI.Methods Eighty patients with acute an-terior wall STEMI who underwent emergency PCI treatment in our hospital from March 2022 to March 2023 were selected as the study subjects,and they were grouped into a observation group(40 cases)and a control group(40 cases)using a ran-dom number table.The control group was treated with conventional drugs and enalapril,and the observation group was treated with sacubitril-valsartan sodium tablets on the basis of the control group.The efficacy,serological indicators,left ventricular function,incidence of major adverse cardiac events(MACE),and adverse reactions during treatment were com-pared before and after treatment.Results The total clinical effective rate of the observation group was obviously higher than that of the control group(97.50%vs.77.50%,χ2/P=7.314/0.007).Compared with the same group before treatment,the N-terminal pro-brain natriuretic peptide(NT-proBNP),cardiac troponin I(cTnI),hypersensitive C-reactive protein(hs-CRP),left ventricular end diastolic volume(LVEDV),left ventricular end systolic volume(LVESV)in both groups obviously de-creased after treatment,left ventricular ejection fraction(LVEF)obviously increased,and the changes in various indicators in the observation group were greater than those in the control group(t/P= 5.507/<0.001,11.006/<0.001,5.287/<0.001,4.297/<0.001,6.647/<0.001,2.330/0.022).The incidence of MACEin the control group was higher than that in the observa-tion group(5.00%vs.20.00%,χ2/P=4.114/0.043).Conclusion Sacubitril-valsartan has an obvious efficacy on patients with acute anterior wall ST segment elevation myocardial infarction undergoing emergency PCI,it can improve cardiac func-tion and the incidence of MACE,and is relatively safe.